Ravi K Amaravadi

faculty photo
Associate Professor of Medicine at the Hospital of the University of Pennsylvania
Attending Physician , Hospital of the University of Pennsylvania
Member, Institute of Translational Medicine and Therapeutics
Member, Abramson Cancer Center
Member, University of Pennsylvania GI Center for Molecular Studies of Digestive and Liver Diseases
Co-Leader Cancer Therapeutics Program , Abramson Cancer Center, University of Pennsylvania
Department: Medicine

Contact information
Division of Hematology Oncology
8 BRB - Room 852
Philadelphia, PA 19104
Office: 215-769-5159
Education:
BA (Biochemistry )
Columbia University , 1996.
MD (Medicine)
Johns Hopkins University , 2000.
Permanent link
 

Description of Research Expertise

Autophagy, Mechanisms of Cell Death, Developmental Therapeutics

Description of Itmat Expertise

Dr. Amaravadi conducts basic, preclinical and Phase I/II clinical trials in novel molecularly targeted therapeutics and combinations in cancer therapy.

Selected Publications

Yam Clinton, Xu Xiaowei, Davies Michael A, Gimotty Phyllis A, Morrissette Jennifer J D, Tetzlaff Michael T, Wani Khalida M, Liu Shujing, Deng Wanleng, Buckley Meghan, Zhao Jianhua, Amaravadi Ravi K, Haas Naomi B, Kudchadkar Ragini R, Pavlick Anna C, Sosman Jeffrey A, Tawbi Hussein, Walker Luke, Schuchter Lynn M, Karakousis Giorgos C, Gangadhar Tara C: A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 24(1): 22-32, Jan 2018.

Sinnamon Andrew J, Neuwirth Madalyn G, Gimotty Phyllis A, Gangadhar Tara C, Amaravadi Ravi K, Schuchter Lynn M, Karakousis Giorgos C: Association of First-in-Class Immune Checkpoint Inhibition and Targeted Therapy With Survival in Patients With Stage IV Melanoma. JAMA oncology 4(1): 126-128, Jan 2018.

Nti Akosua A, Serrano Leona W, Sandhu Harpal S, Uyhazi Katherine E, Edelstein Ilaina D, Zhou Elaine J, Bowman Scott, Song Delu, Gangadhar Tara C, Schuchter Lynn M, Mitnick Sheryl, Huang Alexander, Nichols Charles W, Amaravadi Ravi K, Kim Benjamin J, Aleman Tomas S: FREQUENT SUBCLINICAL MACULAR CHANGES IN COMBINED BRAF/MEK INHIBITION WITH HIGH-DOSE HYDROXYCHLOROQUINE AS TREATMENT FOR ADVANCED METASTATIC BRAF MUTANT MELANOMA: Preliminary Results From a Phase I/II Clinical Treatment Trial. Retina (Philadelphia, Pa.) Jan 2018.

Garman Bradley, Anastopoulos Ioannis N, Krepler Clemens, Brafford Patricia, Sproesser Katrin, Jiang Yuchao, Wubbenhorst Bradley, Amaravadi Ravi, Bennett Joseph, Beqiri Marilda, Elder David, Flaherty Keith T, Frederick Dennie T, Gangadhar Tara C, Guarino Michael, Hoon David, Karakousis Giorgos, Liu Qin, Mitra Nandita, Petrelli Nicholas J, Schuchter Lynn, Shannan Batool, Shields Carol L, Wargo Jennifer, Wenz Brandon, Wilson Melissa A, Xiao Min, Xu Wei, Xu Xaiowei, Yin Xiangfan, Zhang Nancy R, Davies Michael A, Herlyn Meenhard, Nathanson Katherine L: Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines. Cell reports 21(7): 1936-1952, Nov 2017.

Lu Hezhe, Liu Shujing, Zhang Gao, Bin Wu , Zhu Yueyao, Frederick Dennie T, Hu Yi, Zhong Wenqun, Randell Sergio, Sadek Norah, Zhang Wei, Chen Gang, Cheng Chaoran, Zeng Jingwen, Wu Lawrence W, Zhang Jie, Liu Xiaoming, Xu Wei, Krepler Clemens, Sproesser Katrin, Xiao Min, Miao Benchun, Liu Jianglan, Song Claire D, Liu Jephrey Y, Karakousis Giorgos C, Schuchter Lynn M, Lu Yiling, Mills Gordon, Cong Yusheng, Chernoff Jonathan, Guo Jun, Boland Genevieve M, Sullivan Ryan J, Wei Zhi, Field Jeffrey, Amaravadi Ravi K, Flaherty Keith T, Herlyn Meenhard, Xu Xiaowei, Guo Wei: PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas. Nature 550(7674): 133-136, Sep 2017.

Ndoye Abibatou, Budina-Kolomets Anna, Kugel Curtis H, Webster Marie R, Kaur Amanpreet, Behera Reeti, Rebecca Vito W, Li Ling, Brafford Patricia A, Liu Qin, Vashisht Gopal Y N, Davies Michael A, Mills Gordon B, Xu Xiaowei, Wu Hong, Herlyn Meenhard, Nicastri Michael C, Winkler Jeffrey D, Soengas Maria S, Amaravadi Ravi K, Murphy Maureen E, Weeraratna Ashani T: ATG5 mediates a positive feedback loop between Wnt signaling and autophagy in melanoma. Cancer research 77(21): 5873-5885, Sep 2017.

Zhang Ying, Kurupati Raj, Liu Ling, Zhou Xiang Yang, Zhang Gao, Hudaihed Abeer, Filisio Flavia, Giles-Davis Wynetta, Xu Xiaowei, Karakousis Giorgos C, Schuchter Lynn M, Xu Wei, Amaravadi Ravi, Xiao Min, Sadek Norah, Krepler Clemens, Herlyn Meenhard, Freeman Gordon J, Rabinowitz Joshua D, Ertl Hildegund C J: Enhancing CD8(+) T Cell Fatty Acid Catabolism within a Metabolically Challenging Tumor Microenvironment Increases the Efficacy of Melanoma Immunotherapy. Cancer Cell 32(3): 377-391.e9, Sep 2017.

Rebecca Vito W, Nicastri Michael C, McLaughlin Noel, Fennelly Colin, McAfee Quentin, Ronghe Amruta, Nofal Michel, Lim Chun-Yan, Witze Eric, Chude Cynthia I, Zhang Gao, Alicea Gretchen M, Piao Shengfu, Murugan Sengottuvelan, Ojha Rani, Levi Samuel M, Wei Zhi, Barber-Rotenberg Julie S, Murphy Maureen E, Mills Gordon B, Lu Yiling, Rabinowitz Joshua, Marmorstein Ronen, Liu Qin, Liu Shujing, Xu Xiaowei, Herlyn Meenhard, Zoncu Roberto, Brady Donita C, Speicher David W, Winkler Jeffrey D, Amaravadi Ravi K: A unified approach to targeting the lysosome's degradative and growth signaling roles. Cancer discovery 7(11): 1266-1283, Sep 2017.

Gangadhar Tara C, Savitch Samantha L, Yee Stephanie S, Xu Wei, Huang Alexander C, Harmon Shannon, Lieberman David B, Soucier Devon, Fan Ryan, Black Taylor A, Morrissette Jennifer J D, Salathia Neeraj, Waters Jill, Zhang Shile, Toung Jonathan, van Hummelen Paul, Fan Jian-Bing, Xu Xiaowei, Amaravadi Ravi K, Schuchter Lynn M, Karakousis Giorgos C, Hwang Wei-Ting, Carpenter Erica L: Feasibility of monitoring advanced melanoma patients using cell-free DNA from plasma. Pigment cell & melanoma research 31(1): 73-81, Aug 2017.

Izar Benjamin, Sharfman William, Hodi F Stephen, Lawrence Donald, Flaherty Keith T, Amaravadi Ravi, Kim Kevin B, Puzanov Igor, Sosman Jeffrey, Dummer Reinhard, Goldinger Simone M, Lam Lyhping, Kakar Shefali, Tang Zhongwen, Krieter Oliver, McDermott David F, Atkins Michael B: A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status. Cancer medicine 6(8): 1904-1914, Aug 2017.

back to top
Last updated: 08/28/2018
The Trustees of the University of Pennsylvania